Make your money go further for just 25p per day

Up more 12,000% in a year, but is it really still good value?

02/11/2020 · Novacyt SA (NCYT) 

Coronavirus microscopic image

This Covid-19 testing specialist has been a major winner from the pandemic. With the shares up over 12,000% in the past 12 months, can they really still be considered good value, as some contend? Our research into the phenomena that is Novacyt reflects on the facts, opportunities and risks.

Novacyt SA (LON:NCTR, PAR:ALNOV) is an international diagnostics group involved in the sale of diagnostic and pathogen testing kits based on molecular and protein testing technologies. We have followed the stock with interest in our regular Coronavirus updates, since February 2020 when we commented on Novacyt’s big break.

While its main activities are principally based in the UK, the holding company is incorporated in France and ‘listed’ on AIM and Euronext Growth Paris stock markets. For…

Sign up and read the full article

Register to continue reading our content.

Get FREE access now

Already a member? Login

Previous article Next article

Have your say

Log in or register to view or add comments.

For access to the top news and insights from the investment world


Become a Champion Investor for just £90 a year.


More on Novacyt SA

Investing success and new assays

02/02/2021 · Company Insights

After a volatile start to 2021, the share price of last year’s top AIM performer received…

Novacyt: on these numbers, the cheapest stock on the market

29/01/2021 · Company Insights

AIM’s top performer from 2020 announces fabulous numbers, but that was last year, what of the…

More Company Insights

Time to buy the advertising giant?

01/03/2021 · WPP

Investing for growth


Stonking Small Caps: impressive growth here